Evidence map›Paper›PMID 42212209›Full record

ReviewIranian journal of basic medical sciences2026

Cannabidiol: Pharmaceutical formulations and biomedical applications.

Ali Fadavi Eslam, Leila Mohtashami, Parvin Moghimi, Mehrdad Iranshahi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ali Fadavi EslamDepartment of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Leila MohtashamiDepartment of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Parvin MoghimiBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Mehrdad IranshahiBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cannabidiol (CBD) is a phytocannabinoid compound that can be utilized in different pharmaceutical industries. However, high lipophilicity and extensive first-pass metabolism limit its further applications. Therefore, the development of delivery approaches to overcome these obstacles has been of great interest. Herein, a comprehensive review of CBD, the receptors it targets, pharmacokinetic studies, and pharmaceutical formulations for effective delivery is presented. A comprehensive search was conducted in the Scopus, Web of Science, PubMed, and Google Scholar databases from 2016 to 2025. Different

Indexed as

CannabidiolCannabis sativaIntranasal deliveryNanotechnologyOral deliveryPulmonary deliveryTransmucosal delivery

Identifiers

PMID42212209
PMCPMC13213429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.